Department of Breast Surgery, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Breast Cancer Res Treat. 2021 Jun;187(2):417-425. doi: 10.1007/s10549-021-06114-w. Epub 2021 Mar 19.
We compared oncologic outcomes between breast cancer patients who underwent immediate implant-based breast reconstruction (IBBR) and those who underwent autologous flap reconstruction (AFR) after neoadjuvant chemotherapy (NACT).
The study group comprised 536 patients with primary breast cancer who underwent NACT followed by immediate IBBR or AFR. After propensity score matching, 138 patients in the IBBR group and 276 patients in the AFR group were selected for comparisons of locoregional recurrence-free survival (LRRFS), disease-free survival (DFS), distant metastasis-free survival (DMFS), and breast cancer-specific survival (BCSS).
No significant differences were observed between the matched groups in locoregional recurrence rates (IBBR vs. AFR: 12.3% vs. 12%; P = 0.915) and distant metastasis (13% vs. 17%; P = 0.293). There was also no significant difference between the groups in LRRFS (P = 0.956), DFS (P = 0.606), DMFS (P = 0.283), or BCSS (P = 0.121). The 5- and 10-year LRRFS rates were 87.6% and 85.9% in the IBBR group, and 87.7% and 86.1% in the AFR group; the 5- and 10-year DFS rates were 79% and 77.5% in the IBBR group, and 77% and 75% in the AFR group; the 5- and 10-year DMFS rates were 85.9% and 85.9% in the IBBR group, and 83.2% and 81.8% in the AFR group; and the 5- and 10-year BCSS rates were 97.8% and 91.3% in the IBBR group, and 91.8% and 86% in the AFR group, respectively.
In this propensity score-matched analysis of oncologic outcomes in breast cancer patients who underwent immediate reconstruction after NACT, no significant differences were observed between the IBBR and AFR groups.
我们比较了接受新辅助化疗（NACT）后行即刻乳房重建（IBBR）和自体皮瓣重建（AFR）的乳腺癌患者的肿瘤学结局。
研究组纳入 536 例接受 NACT 后行即刻 IBBR 或 AFR 的原发性乳腺癌患者。经过倾向评分匹配后，选择 138 例 IBBR 组患者和 276 例 AFR 组患者进行局部区域无复发生存（LRRFS）、无病生存（DFS）、远处无转移生存（DMFS）和乳腺癌特异性生存（BCSS）的比较。
匹配组间局部区域复发率（IBBR 与 AFR：12.3%与 12%；P=0.915）和远处转移率（13%与 17%；P=0.293）无显著差异。LRRFS（P=0.956）、DFS（P=0.606）、DMFS（P=0.283）和 BCSS（P=0.121）方面两组间也无显著差异。IBBR 组的 5 年和 10 年 LRRFS 率分别为 87.6%和 85.9%，AFR 组分别为 87.7%和 86.1%；IBBR 组的 5 年和 10 年 DFS 率分别为 79%和 77.5%，AFR 组分别为 77%和 75%；IBBR 组的 5 年和 10 年 DMFS 率分别为 85.9%和 85.9%，AFR 组分别为 83.2%和 81.8%；IBBR 组的 5 年和 10 年 BCSS 率分别为 97.8%和 91.3%，AFR 组分别为 91.8%和 86%。
在这项 NACT 后即刻重建的乳腺癌患者肿瘤学结局的倾向评分匹配分析中，IBBR 组和 AFR 组之间未观察到显著差异。
